(59 days)
Boston Original Cleaner is indicated for use to clean silicone acrylate and fluoro silicone acrylate gas permeable contact lenses after each removal and before conditioning (wetting, soaking, disinfecting).
Boston Original Conditioning Solutions is indicated for wetting, disinfecting and soaking (after cleaning and rinsing) of fluoro silicone acrylate and silicone acrylate gas permeable contact lenses.
Boston Original Cleaner is a sterile, concentrated, homogeneous surfactant solution containing alkyl ether sulfate and silica gel as cleaning agents, titanium dioxide and fragrance.
Boston Original Conditioning Solutions is a sterile, aqueous buffered, solution containing a cellulosic viscosifier, cationic cellulose derivative polymer and polyvinyl alcohol as wetting and cushioning agents; preserved with chlorhexidine gluconate (0.006%) and edetate disodium (EDTA) (0.05%).
The provided document is a 510(k) Premarket Notification for Bausch + Lomb Boston Original Cleaner and Boston Original Conditioning Solutions. It focuses on demonstrating the substantial equivalence of a modified regimen for using these existing contact lens care products, specifically replacing a water rinse with Bausch + Lomb Sensitive Eyes Plus Saline Solution.
Therefore, the acceptance criteria and supporting studies are related to proving the safety and effectiveness of this modified regimen, not a new device.
Here's a breakdown of the requested information based on the provided text, noting where information is not applicable or explicitly stated for this type of submission:
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria (for the modified regimen) | Reported Device Performance (Summary of Test Results) |
|---|---|
| Microbiology - Antimicrobial Preservative Efficacy (for discard dating): Meet requirements of ISO 14730, Annex C. | Both Boston Original Cleaner and Boston Original Conditioning Solutions (test articles) met the requirements of ISO 14730, Annex C for antimicrobial preservative efficacy testing and guidance on determining discard date, initially and after simulated use for the proposed 90-day discard dates. |
| Microbiology - Regimen Evaluation: Meet FDA performance criteria for regimen evaluation as described in the May 1, 1997 Guidance for Industry, Pre-market Notification (510(k)) Guidance Document for Contact Lens Care Products, when used in a 10-second rub, 5-second rinse (per lens side) regimen. Also meet ISO Standard 14729:2001/Amd. 1:2010 (E) for regimen testing. | The modified regimen (replacing tap water with Sensitive Eyes Plus Saline Solution) met the FDA performance criteria for regimen evaluation as described in the May 1, 1997 Guidance. The products used in this regimen also met the performance criteria established in ISO Standard 14729:2001/Amd. 1:2010 (E) for regimen testing. (Note: Regimen testing was previously reviewed as part of K170483 for Sensitive Eyes Plus Saline Solution.) |
| Biocompatibility: (Implied need to ensure continued biocompatibility of the lens care system) | Biocompatibility tests were deemed "unnecessary for this application" as previous data submitted for K980133 (Boston Original Conditioning Solutions) and P820069 (Boston Original Cleaner) were still applicable. This indicates that the predicate device's biocompatibility was accepted as sufficient for the modified regimen. |
| Lens Compatibility: Ensure the modified regimen is compatible with gas permeable contact lenses. | The results of lens compatibility studies per ISO 11981 demonstrate that replacing water with Bausch + Lomb Sensitive Eyes Plus Saline Solution as part of the regimen is compatible with gas permeable contact lenses. |
| Clinical Data: (Implied need to ensure the modified regimen is safe and effective in vivo) | Clinical studies were "unnecessary for this application." The submission states, "This Cleaner - Conditioning System has been commercially available in the market for almost 20 years with well demonstrated safety and efficacy." This implies that extensive real-world usage of the existing products, coupled with the lab testing on the modified regimen, was sufficient to demonstrate substantial equivalence without new human clinical trials for this specific change. |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify sample sizes for the individual microbiological and lens compatibility test sets. It refers generally to "studies" and "results."
- Data Provenance: The studies were preclinical (laboratory testing). The specific country of origin for the lab work is not stated, but given it's a US FDA submission for a US-based company, it's likely conducted in the US or by a contracted lab. The studies are prospective for the modified regimen comparison.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications
This information is not applicable in the context of this submission. The "ground truth" for these types of tests (microbiology, lens compatibility) is established by adherence to specific, validated international standards (ISO standards) and FDA guidance documents. There isn't a need for expert consensus on individual results in the way there would be for, say, image interpretation in a diagnostic AI device.
4. Adjudication Method for the Test Set
This is not applicable. Adjudication methods like 2+1 or 3+1 are used in studies involving human interpretation (e.g., radiologists reviewing images) to establish a consensus "ground truth." For laboratory tests like those described, the results are quantitative and objective, measured against predefined acceptance criteria from standards.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done
No, an MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic devices involving human readers (e.g., AI for medical imaging). The submission addresses chemical solutions and their compatibility/efficacy, which are not evaluated through MRMC studies.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done
This question is not applicable as the submission is not for an AI/algorithm-based device. The "device" here refers to contact lens cleaning and conditioning solutions.
7. The Type of Ground Truth Used
The "ground truth" for the performance of these solutions is established through:
- Adherence to International Standards (ISO): Specifically ISO 14730 (Antimicrobial preservative efficacy), ISO 14729 (Regimen testing), and ISO 11981 (Lens compatibility).
- Adherence to FDA Guidance Documents: "Pre-market Notification (510(k)) Guidance Document for Contact Lens Care Products, May 1, 1997."
- Validated Laboratory Methods: Results are compared against specific quantitative thresholds defined by these standards and guidance.
- Historical Data: The "almost 20 years" of commercial availability of the existing products with "well demonstrated safety and efficacy" serves as substantial baseline "ground truth" for the system as a whole, negating the need for new clinical trials for a modified rinse step.
8. The Sample Size for the Training Set
This question is not applicable. There is no "training set" as this is not an AI/machine learning device.
9. How the Ground Truth for the Training Set Was Established
This question is not applicable as there is no "training set."
{0}------------------------------------------------
November 27, 2017
Bausch & Lomb Incorporated Melissa Thomas Senior Manager Regulatory Affairs 1400 North Goodman Street Rochester, NY 14609
Re: K173089
Trade/Device Name: Bausch + Lomb Boston Original Cleaner, Bausch + Lomb Boston Original Conditioning Solutions Regulation Number: 21 CFR 886.5918 Regulation Name: Rigid Gas Permeable Contact Lens Care Products Regulatory Class: Class II Product Code: MRC Dated: October 1, 2017 Received: October 5, 2017
Dear Melissa Thomas:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
{1}------------------------------------------------
You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Denise L. Hampton -S
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K173089
Device Name
Bausch + Lomb Boston Original Cleaner Bausch + Lomb Boston Original Conditioning Solutions
Indications for Use (Describe)
Boston Original Cleaner is indicated for use to clean silicone acrylate and fluoro silicone acrylate gas permeable contact lenses after each removal and before conditioning (wetting, soaking, disinfecting).
Boston Original Conditioning Solutions is indicated for wetting, disinfecting and soaking (after cleaning and rinsing) of fluoro silicone acrylate and silicone acrylate gas permeable contact lenses.
| Type of Use (Select one or both, as applicable) | ||
|---|---|---|
| Registration Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart G) | Registration Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart G) |
| Registration Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart G) |
_ | Prescription Use (Part 21 CFR 801 Subpart D)
|X Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) SUMMARY
Bausch + Lomb Boston Original Cleaner & Boston Original Conditioning Solutions
1. Submitter Information
| Primary | Alternate |
|---|---|
| Melissa Thomas | Glenn Davies, O.D. |
| Senior Manager, Regulatory Affairs1400 North Goodman Street | Sr. Director Regulatory Affairs,1400 North Goodman Street |
| Rochester, NY 14609 | Rochester, NY 14609 |
| Tel. (585) 338-6045 | Tel. (585) 338-8215 |
| Fax (585) 338-0702 | Email: Glenn.Davies@bausch.com |
| Email: Melissa.Thomas@bausch.com |
Summary Prepared: September 27, 2017
2. Device Name
| Trade Name: | Bausch + Lomb Boston Original CleanerBausch + Lomb Original Conditioning Solutions |
|---|---|
| Classification: | Accessories, Contact Lens Care Products |
| Device classification: | Class II |
| Regulation Number: | 886.5918 Rigid Gas Permeable Contact Lens CareProducts |
| Product Code: | MRC |
3. Predicate Device
Bausch + Lomb Boston Original Cleaner (P820069) Bausch + Lomb Boston Original Conditioning Solutions (K980133) Bausch + Lomb Sensitive Eyes Plus Saline Solution (K170483)
4. Description of the Device
Boston Original Cleaner is a sterile, concentrated, homogeneous surfactant solution containing alkyl ether sulfate and silica gel as cleaning agents, titanium dioxide and fragrance.
Boston Original Conditioning Solutions is a sterile, aqueous buffered, solution containing a cellulosic viscosifier, cationic cellulose derivative polymer and
{4}------------------------------------------------
polyvinyl alcohol as wetting and cushioning agents; preserved with chlorhexidine gluconate (0.006%) and edetate disodium (EDTA) (0.05%).
5. Intended Use
Boston Original Cleaner is indicated for use to clean silicone acrylate and fluoro silicone acrylate gas permeable contact lenses after each removal and before conditioning (wetting, soaking, disinfecting).
Boston Original Conditioning Solutions is indicated for wetting, disinfecting and soaking (after cleaning and rinsing) of fluoro silicone acrylate and silicone acrylate gas permeable contact lenses.
6. Description of Safety and Substantial Equivalence
A series of preclinical testing was performed to demonstrate the safety and effectiveness of the modified regimen which replaces the water rinse with Bausch + Lomb Sensitive Eyes Plus Saline Solution as described in Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products, May 1, 1997. A brief summary of the test results is provided below:
Microbiology
Studies were previously performed to establish discard dating for both Boston Original Cleaner and Boston Original Conditioning Solutions. The test articles were evaluated initially and again following simulated use for the proposed 90 day discard dates.
The results of these evaluations demonstrate that both solutions meet the requirements of ISO 14730, Annex C, Ophthalmic optics - Contact lens care products - Antimicrobial preservative efficacy testing and guidance on determining discard date.
Additionally a modified regimen procedure allowing for a rinse with Sensitive Eyes Plus Saline Solution in place of tap water was conducted. The results demonstrate that modified regimen with Sensitive Eyes Plus Saline Solution meets the FDA performance criteria for regimen evaluation as described in the May 1, 1997 Guidance for Industry, Pre-market Notification (510(k)) Guidance Document for Contact Lens Care Products when used in a 10 second rub, 5 second rinse (per lens side) regimen. The products used in this regimen also meet the performance criteria established in ISO Standard 14729: 2001/Amd. 1:2010: (E) for regimen testing. Regimen testing was previously reviewed as part of K170483.
Biocompatibility
Biocompatibility tests were unnecessary for this application. Previous data submitted is still applicable, please reference K980133 for Boston Original Conditioning Solutions, and P820069 for Boston Original Cleaner.
Lens Compatibility
The results of lens compatibility studies per ISO 11981 demonstrate that replacing water with Bausch + Lomb Sensitive Eyes Plus Saline Solution as part of the regimen is compatible with gas permeable contact lenses.
{5}------------------------------------------------
Clinical Data
Clinical studies involving the modified regimen for Boston Original Cleaner and Conditioning Solutions were unnecessary for this application. This Cleaner -Conditioning System has been commercially available in the market for almost 20 years with well demonstrated safety and efficacy.
7. Substantial Equivalence
The cumulative results of laboratory testing sponsored by Bausch + Lomb demonstrate that the safety, effectiveness and performance of the modified regimen for Boston Original Cleaner and Conditioning Solutions to include Bausch + Lomb Sensitive Eyes Plus Saline Solution when used with gas permeable contact lenses are substantially equivalent to the current regimen with a water rinse.
§ 886.5918 Rigid gas permeable contact lens care products.
(a)
Identification. A rigid gas permeable contact lens care product is a device intended for use in the cleaning, conditioning, rinsing, lubricating/rewetting, or storing of a rigid gas permeable contact lens. This includes all solutions and tablets used together with rigid gas permeable contact lenses.(b)
Classification. Class II (Special Controls) Guidance Document: “Guidance for Industry Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products.”